	Kei Muro, MD, of the Aichi Cancer Center Hospital in Nagoya, Japan, discusses updated findings from the KEYNOTE-012 study, which looked at pembrolizumab for the treatment of several types of cancer.

	Muro recently presented on the gastric cancer cohort of KEYNOTE-012, which included 39 patients whose tumors expressed PD-L1. The study included 19 Asian and 22 non-Asian patients.

	The objective response rate (ORR) was 22.2% and the toxicity profile was very manageable. Median progression-free survival (PFS) was 1.9 months and at 6 months, the PFS rate was 24%, and the overall survival (OS) rate was 69%.  

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Immuno-Oncology

Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Gastrointestinal Cancers Symposium (ASCO GI)

Conference

ELI-22-OSD1267 - /conference/gi

Kei Muro, MD, of the Aichi Cancer Center Hospital in Nagoya, Japan, discusses updated findings from the KEYNOTE-012 study, which looked at pembrolizumab for the treatment if several types of cancer.

Dr. Muro on Pembrolizumab for Gastric Cancer